Clinical trials: in Panama
Chronic Hepatitis B, Hepatitis B, Chronic
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as…
- Trial name
- NCT05630807
- Testing
- Bepirovirsen
- Where
- 177 sites in United States, Argentina and 24 more
- Volunteers
- 981 people
- Sponsor
- GlaxoSmithKline
Primary Open Angle Glaucoma, Cataract
A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)
A study to assess the safety of the Helix Surgical System in cataract surgery and to gain early evidence of its effectiveness in lowering intraocular pressure (IOP) in subjects with mild to moderate primary open-angle glaucoma…
- Trial name
- HELIX (NCT06948773)
- Testing
- Helix Surgical System
- Where
- Panama
- Volunteers
- 25 people
- Sponsor
- Sight Sciences, Inc.
Respiratory Syncytial Virus, Human Metapneumovirus
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in…
- Trial name
- NCT05743881
- Testing
- mRNA-1345, mRNA-1365, Nimenrix
- Where
- 17 sites in United States, Panama and 1 more
- Volunteers
- 186 people
- Sponsor
- ModernaTX, Inc.
Benign Prostatic Hyperplasia
A Pilot Study Of The ALPFA Benign Prostatic Hyperplasia (BPH) Pulsed Field Ablation (PFA) System
The ALPFA Medical BPH Pilot Study is a prospective, open label, single arm pilot study to assess the use of the ALPFA BPH PFA System in the treatment of men over the age of 45 with obstructive urinary symptoms associated with…
- Trial name
- NCT06965582
- Testing
- ALPFA BPH PFA System
- Where
- 4 sites in Czechia, Italy and 1 more
- Volunteers
- 100 people
- Sponsor
- ALPFA Medical
Systemic Lupus Erythematosus
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
This is a 2-part study of GSK5926371 in participants with autoimmune rheumatic diseases (ARD). In part 1, participants will receive different doses of GSK5926371 to find a suitable priming dose.
- Trial name
- ELEVATE-1 (NCT07371468)
- Testing
- GSK5926371
- Where
- 19 sites in Argentina, Brazil and 7 more
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Dermatitis, Atopic
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
- Trial name
- AtDvance (NCT06447506)
- Testing
- GSK1070806
- Where
- 51 sites in United States, Argentina and 13 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Open Angle Glaucoma, Ocular Hypertension
MINIject Global Long-Term Follow-up Study
The study will assess the long-term (up to 5 years) safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.
- Trial name
- STAR-GLOBAL (NCT04524416)
- Testing
- Minimally invasive glaucoma surgery (MIGS)
- Where
- 9 sites in Colombia, France and 4 more
- Volunteers
- 116 people
- Sponsor
- iSTAR Medical
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born…
- Trial name
- NCT06143046
- Testing
- mRNA-1345
- Where
- 56 sites in United States, Canada and 6 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
HIV Infections, HIV-1
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible…
- Trial name
- NCT00980538
- Testing
- Etravirine
- Where
- 29 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Janssen Sciences Ireland UC
Dermatitis, Atopic
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who…
- Trial name
- AtDventure (NCT05999799)
- Testing
- GSK1070806
- Where
- 89 sites in United States, Argentina and 15 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline
Neoplasms
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227.
- Trial name
- PanTumor-101 (NCT06551142)
- Testing
- Ris-Rez, Cisplatin, Carboplatin
- Where
- 67 sites in United States, Argentina and 11 more
- Volunteers
- 845 people
- Sponsor
- GlaxoSmithKline
Acute Gastroenteritis, Norovirus Acute Gastroenteritis
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE)…
- Trial name
- Nova 301 (NCT06592794)
- Testing
- mRNA-1403
- Where
- 283 sites in United States, Australia and 5 more
- Volunteers
- 37,864 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Prostate Cancer
Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue
This goal of this clinical trial is to determine if the Vanquish System can safely and effectively treat cancerous tissue in the prostate.
- Trial name
- PERI III (NCT07561502)
- Testing
- Water Vapor Ablation
- Where
- Panama
- Volunteers
- 32 people
- Sponsor
- Francis Medical Inc.
Neoplasms
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc).
- Trial name
- NCT06077877
- Testing
- GSK4524101, Niraparib
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Peripheral Nerve Disorder
Early Feasibility of the Nervonik Peripheral Nerve Stimulation Device
A multicenter, 30 patient prospective single arm evaluation of the Nervonik system in symptomatic patients with chronic severe knee, elbow or shoulder pain.
- Trial name
- NCT06772142
- Testing
- Peripheral Nerve Stimulation
- Where
- Panama
- Volunteers
- 30 people
- Sponsor
- Nervonik
Psoriasis
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque…
- Trial name
- NCT03988439
- Testing
- IDP-118 Lotion
- Where
- 9 sites in United States, Dominican Republic and 1 more
- Volunteers
- 16 people
- Sponsor
- Bausch Health Americas, Inc.
Refractive Error Correction
Clinical Outcomes of the Use of a Femtosecond Laser on an Implanted Intraocular Lens
This is a prospective non-randomized patient controlled single center study which is designed to evaluate the clinical outcomes of the treatment of an implanted intraocular lens using a low-energy femtosecond laser for refractive…
- Trial name
- NCT07473557
- Testing
- Device
- Where
- Panama
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Perfect Lens, LLC
Respiratory Syncytial Virus Infections
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
The purpose of this follow-up study was to describe the safety in subsequent pregnancies in participants who were previously administered the RSVPreF3 maternal vaccine or control during any prior RSV MAT study.
- Trial name
- NCT05705440
- Testing
- RSVPreF3 vaccine, Control
- Where
- 138 sites in United States, Argentina and 21 more
- Volunteers
- 3,855 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in patients with programmed death-ligand 1 (PD-L1)-positive cervical cancer (metastatic…
- Trial name
- SKYSCRAPER-04 (NCT04300647)
- Testing
- Tiragolumab, Atezolizumab
- Where
- 58 sites in United States, Australia and 15 more
- Volunteers
- 172 people
- Sponsor
- Hoffmann-La Roche
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by…
- Conditions
- RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms
- Trial name
- AcceleRET-Lung (NCT04222972)
- Testing
- Pralsetinib, Carboplatin, Cisplatin
- Where
- 74 sites in Argentina, Australia and 20 more
- Volunteers
- 223 people
- Sponsor
- Hoffmann-La Roche